Tesamorelin and visceral fat: the evidence

This article is educational. Nothing here is medical advice, and nothing should be read as a recommendation to start, stop, or adjust any medicine, peptide, or supplement. Decisions of that kind belong with a clinician who knows your history.

Community forums are full of posts from people who have made real progress on a GLP-1 agonist and then started asking what comes next. A common thread: someone mentions tesamorelin for the stubborn abdominal fat that persists after significant weight loss. The question is reasonable. The answer is more specific than most posts suggest.

What tesamorelin actually is

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that tells the pituitary gland to release growth hormone (GH). Rather than delivering GH directly (as recombinant HGH does), tesamorelin stimulates the pituitary to release its own GH in a pulsatile pattern that broadly mirrors the body's normal rhythm^[5].

In the United States it is sold as Egrifta SV by Theratechnologies. The prescribing information describes one approved indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy^[1]. That narrow approval matters for everything that follows.

The approved indication and why it is specific

HIV-associated lipodystrophy is not simply excess abdominal fat. It is an abnormal fat redistribution syndrome that develops in some people living with HIV, partly as a consequence of antiretroviral therapy. Visceral adipose tissue (the fat around abdominal organs) accumulates atypically. Two phase-3 randomised controlled trials in this population showed that daily tesamorelin produced a meaningful reduction in visceral fat versus placebo at 26 weeks^[4].

A 2024 analysis in the journal AIDS confirmed that this effect extends to HIV patients on integrase-inhibitor regimens (which became the dominant treatment class after the original trials). The tesamorelin group showed a median visceral fat decrease of 25 cm squared, while the placebo group showed a median increase of 14 cm squared (P = 0.001)^[2].

The population in these trials is defined: adults with HIV, on antiretroviral therapy, with documented lipodystrophy. The effect size reported in the trials is for that population. Applying those numbers to a person without HIV who has reached a weight plateau after a GLP-1 programme is a different question, and one the published trial literature has not answered.

What the research does not show

There are no published randomised controlled trials examining tesamorelin specifically for visceral fat reduction in people without HIV. Off-label use in otherwise healthy adults with metabolic-pattern abdominal fat is discussed in forums and sometimes in clinic, but the evidence base for that use is observational at best. The mechanism is plausible, but plausibility is not the same as demonstrated efficacy.

A 2020 randomised trial in JCI Insight found that tesamorelin reduced liver fat and appeared to prevent fibrosis progression in HIV patients with non-alcoholic fatty liver disease, adding to the metabolic picture for the approved population^[3]. Whether those liver effects translate to people without HIV and without underlying antiretroviral-therapy-related metabolic changes is unknown.

On subcutaneous fat (the fat just under the skin, including around the abdomen), the trial data are consistently unimpressive. The visceral-fat effect in the approved population does not extend meaningfully to subcutaneous fat. For someone asking whether tesamorelin will help reduce the fat they can see and feel around their waist after weight loss, the honest answer from the literature is: probably not for that type of fat.

Safety signals worth knowing before a clinician conversation

The Egrifta SV prescribing information lists the most common adverse reactions (greater than 5 percent of patients) as arthralgia, injection-site erythema and pruritus, pain in extremities, peripheral oedema, and myalgia^[1]. Elevated IGF-1, fluid retention, and glucose intolerance are also flagged. Active malignancy and disrupted pituitary or hypothalamic function are contraindications. These are signals established in the HIV-lipodystrophy population; the profile in healthy adults without HIV has not been characterised in trials.

The IGF-1 elevation is worth particular attention. The label requires periodic monitoring and recommends considering discontinuation if IGF-1 remains persistently elevated above 3 standard deviation scores above the age- and sex-specific mean. Sustained IGF-1 elevation is a theoretical oncology concern across the GH-axis drug class, and the long-term cancer-incidence data in non-HIV populations simply do not exist.

Access outside the United States

In the EU, EEA, and UK, tesamorelin has no marketing authorisation. Theratechnologies withdrew the EMA application in 2012 and has not re-applied. Lawful access in those jurisdictions runs only through unlicensed-medicine routes where a prescribing clinician requests an import for a specific named patient and takes personal responsibility for the prescription. General online sale is not lawful. See the tesamorelin page for country-by-country detail.

What to ask your clinician

If you are considering tesamorelin after significant weight loss on a GLP-1 programme, a few questions are worth raising with a prescribing clinician before anything else.

First, what is the character of the fat that concerns you? Imaging (DEXA or CT) can distinguish visceral adipose tissue from subcutaneous fat. Tesamorelin's evidence base is for visceral fat in a specific population, and a scan establishes whether that is actually what is present.

Second, what is your baseline IGF-1 and what is your age- and sex-matched reference range? Any GH-axis agent alters IGF-1, and without a baseline you cannot interpret the effect or monitor safety.

Third, given that tesamorelin has no marketing authorisation in the EU or UK, what is the legal access pathway a clinician would use, and who takes prescribing responsibility? The tesamorelin regulatory page covers the regulatory framework, but the specifics depend on your country.

Fourth, is there a weight-loss-related reason visceral fat is persisting that deserves attention first, such as insulin resistance, thyroid status, or cortisol dysregulation? A clinician can screen for those before layering a GH-axis agent on top.